Piper Jaffray Transfers Coverage on Myriad Genetics (MYGN) to Overweight; Attractive Opportunity At Present Levels
Tweet Send to a Friend
Piper Jaffray & Co. transfers coverage on Myriad Genetics (Nasdaq: MYGN) to Overweight. Price target increased $1 to $42.
Piper ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
